Reliability of Implantable Central Venous Access Devices in Patients With Cancer

Gregory V. Stanislav, Robert Joseph Fitzgibbons, Robert T. Bailey, James A. Mailliard, P. Steven Johnson, John B. Feole

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

We reviewed complications requiring removal of Hickman catheters (HCs) and implantable central venous access devices (ICVADs) in patients with cancer over a 30-month period. The study was unique in the sense that patients chose which system would be inserted, unless continuous infusion was anticipated. A total of 115 systems were inserted in 102 patients. Forty-four HCs were inserted in 34 patients (total system days, 8533 [mean, 194 days]); 71 ICVADs were inserted in 68 patients (total system days, 18681 [mean, 263 days]). Complications required removal in 38.6% of HCs and 18.3% of ICVADs. Complication rates were one in 501 days in the HC group and one in 1450 days in the ICVAD group. Although 15 systems were removed for suspected infection, closer analysis revealed that bacteremia ultimately found to be unrelated to the catheter resulted in premature removal in many cases. The catheter tip was located high in the superior vena cava or in the subclavian vein in all systems removed due to thrombosis. Miscellaneous complications in HCs included dislodgment and catheter embolism. The increased longevity, lower complication rate, and decreased maintenance requirements in the use of ICVADs support their superiority over HCs in the treatment of patients with cancer.

Original languageEnglish
Pages (from-to)1280-1283
Number of pages4
JournalArchives of Surgery
Volume122
Issue number11
DOIs
StatePublished - 1987

Fingerprint

Catheters
Equipment and Supplies
Neoplasms
Subclavian Vein
Indwelling Catheters
Superior Vena Cava
Central Venous Catheters
Bacteremia
Embolism
Thrombosis
Maintenance
Infection

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Stanislav, G. V., Fitzgibbons, R. J., Bailey, R. T., Mailliard, J. A., Johnson, P. S., & Feole, J. B. (1987). Reliability of Implantable Central Venous Access Devices in Patients With Cancer. Archives of Surgery, 122(11), 1280-1283. https://doi.org/10.1001/archsurg.1987.01400230066012

Reliability of Implantable Central Venous Access Devices in Patients With Cancer. / Stanislav, Gregory V.; Fitzgibbons, Robert Joseph; Bailey, Robert T.; Mailliard, James A.; Johnson, P. Steven; Feole, John B.

In: Archives of Surgery, Vol. 122, No. 11, 1987, p. 1280-1283.

Research output: Contribution to journalArticle

Stanislav, Gregory V. ; Fitzgibbons, Robert Joseph ; Bailey, Robert T. ; Mailliard, James A. ; Johnson, P. Steven ; Feole, John B. / Reliability of Implantable Central Venous Access Devices in Patients With Cancer. In: Archives of Surgery. 1987 ; Vol. 122, No. 11. pp. 1280-1283.
@article{e37eb6cba21f42168a56a742a46d31c1,
title = "Reliability of Implantable Central Venous Access Devices in Patients With Cancer",
abstract = "We reviewed complications requiring removal of Hickman catheters (HCs) and implantable central venous access devices (ICVADs) in patients with cancer over a 30-month period. The study was unique in the sense that patients chose which system would be inserted, unless continuous infusion was anticipated. A total of 115 systems were inserted in 102 patients. Forty-four HCs were inserted in 34 patients (total system days, 8533 [mean, 194 days]); 71 ICVADs were inserted in 68 patients (total system days, 18681 [mean, 263 days]). Complications required removal in 38.6{\%} of HCs and 18.3{\%} of ICVADs. Complication rates were one in 501 days in the HC group and one in 1450 days in the ICVAD group. Although 15 systems were removed for suspected infection, closer analysis revealed that bacteremia ultimately found to be unrelated to the catheter resulted in premature removal in many cases. The catheter tip was located high in the superior vena cava or in the subclavian vein in all systems removed due to thrombosis. Miscellaneous complications in HCs included dislodgment and catheter embolism. The increased longevity, lower complication rate, and decreased maintenance requirements in the use of ICVADs support their superiority over HCs in the treatment of patients with cancer.",
author = "Stanislav, {Gregory V.} and Fitzgibbons, {Robert Joseph} and Bailey, {Robert T.} and Mailliard, {James A.} and Johnson, {P. Steven} and Feole, {John B.}",
year = "1987",
doi = "10.1001/archsurg.1987.01400230066012",
language = "English",
volume = "122",
pages = "1280--1283",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Reliability of Implantable Central Venous Access Devices in Patients With Cancer

AU - Stanislav, Gregory V.

AU - Fitzgibbons, Robert Joseph

AU - Bailey, Robert T.

AU - Mailliard, James A.

AU - Johnson, P. Steven

AU - Feole, John B.

PY - 1987

Y1 - 1987

N2 - We reviewed complications requiring removal of Hickman catheters (HCs) and implantable central venous access devices (ICVADs) in patients with cancer over a 30-month period. The study was unique in the sense that patients chose which system would be inserted, unless continuous infusion was anticipated. A total of 115 systems were inserted in 102 patients. Forty-four HCs were inserted in 34 patients (total system days, 8533 [mean, 194 days]); 71 ICVADs were inserted in 68 patients (total system days, 18681 [mean, 263 days]). Complications required removal in 38.6% of HCs and 18.3% of ICVADs. Complication rates were one in 501 days in the HC group and one in 1450 days in the ICVAD group. Although 15 systems were removed for suspected infection, closer analysis revealed that bacteremia ultimately found to be unrelated to the catheter resulted in premature removal in many cases. The catheter tip was located high in the superior vena cava or in the subclavian vein in all systems removed due to thrombosis. Miscellaneous complications in HCs included dislodgment and catheter embolism. The increased longevity, lower complication rate, and decreased maintenance requirements in the use of ICVADs support their superiority over HCs in the treatment of patients with cancer.

AB - We reviewed complications requiring removal of Hickman catheters (HCs) and implantable central venous access devices (ICVADs) in patients with cancer over a 30-month period. The study was unique in the sense that patients chose which system would be inserted, unless continuous infusion was anticipated. A total of 115 systems were inserted in 102 patients. Forty-four HCs were inserted in 34 patients (total system days, 8533 [mean, 194 days]); 71 ICVADs were inserted in 68 patients (total system days, 18681 [mean, 263 days]). Complications required removal in 38.6% of HCs and 18.3% of ICVADs. Complication rates were one in 501 days in the HC group and one in 1450 days in the ICVAD group. Although 15 systems were removed for suspected infection, closer analysis revealed that bacteremia ultimately found to be unrelated to the catheter resulted in premature removal in many cases. The catheter tip was located high in the superior vena cava or in the subclavian vein in all systems removed due to thrombosis. Miscellaneous complications in HCs included dislodgment and catheter embolism. The increased longevity, lower complication rate, and decreased maintenance requirements in the use of ICVADs support their superiority over HCs in the treatment of patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023635423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023635423&partnerID=8YFLogxK

U2 - 10.1001/archsurg.1987.01400230066012

DO - 10.1001/archsurg.1987.01400230066012

M3 - Article

C2 - 3675192

AN - SCOPUS:0023635423

VL - 122

SP - 1280

EP - 1283

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 11

ER -